seas

Rapid Flu Tests May Prove Especially Helpful This Season

On October 5, Chiron Corporation notified the CDC that none of its influenza vaccine (Fluvirin) would be available for distribution in the United States for the current influenza season. In the wake of this sudden removal of nearly half of the anticipated American vaccine supply, medical officials and the general public have grown increasingly alarmed about the scarcity of vaccine and the ris...

Appendicitis: Evolving Tools to Diagnose a Classic Disease

Contributing Editor Appendicitis is a common, potentially lethal condition that affects 7% of individuals sometime in their lives. The condition occurs when the appendix, a blind pouch of intestine at the proximal colon, becomes obstructed by mucus, stool, or lymphatic tissue. Infection ensues, which can rapidly evol...

Non-Invasive Diagnostic Tests for Celiac Disease

Celiac disease (CD) is an autoimmune inflammatory disease of the small intestine that is triggered in genetically susceptible persons by the ingestion of the gluten-containing grains wheat, rye, barley, and possibly oats. The condition is thought to result from the activation of both a T-cell and B-cell immune respons...

Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease

DENVER--(BUSINESS WIRE)--Jul 10, 2007 - Corgenix MedicalCorporation (OTC BB: CONX) and the Company's clinical collaboratorsreported new clinical data demonstrating a significant correlationbetween serum levels of the Company's patented AtherOx(TM)bio-markers and cardiovascular disease. The data was presented atthe XXIst Congress of the International Society on Thrombosis andHemostasis (ISTH...

AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease

PORTLAND, Ore.--(BUSINESS WIRE)--Jul 10, 2007 - AVI BioPharma, Inc.(Nasdaq:AVII) announced today that its partner Cook Medical hascompleted target patient enrollment and released six-monthfollow-up data from a Phase II clinical trial known as Appraisal.The trial, currently being held in Germany, was designed to studythe effect of the Neugene(R) antisense drug Resten-MP(TM), whenused in conj...

Samaritan's Alzheimer's Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimer's Disease

Animal Study Confirms Caprospinol's (SP-233) Ability to Clear BrainPlaque and Empower Rat Brain Cells to Recover Memory Function In Vivo 'Proof of Concept' Study Proposes Direct CorrelationBetween Removing Beta Amyloid Plaque and Memory Recovery LAS VEGAS, July 10, 2007 (PRIME NEWSWIRE) -- SamaritanPharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs,is ple...

BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease

WAKEFIELD, Mass.--(BUSINESS WIRE)--Jul 10, 2007 - BusinessWeekpublished an article on July 6 discussing the race bypharmaceutical and biotechnology companies to be first to bring tomarket an effective angiogenesis treatment for cardiovasculardisease. While angiogenesis therapies are being pursued bySanofi-Aventis, Boston Scientific, Baxter, and Genzyme, amongothers, the article highlights a...

Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis

IRVINE, Calif.--(BUSINESS WIRE)--Jul 6, 2007 - Cobalis Corp.(OTCBB:CLSC), a pharmaceutical development company specializing inanti-allergy medications, today reported preliminary top-lineresults from two Phase III clinical trials for its drugPreHistin(TM) in patients with moderate to moderately severeseasonal allergic rhinitis, commonly known as hay fever. The trialsshowed very low symptom...

BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease

WAKEFIELD, Mass.--(BUSINESS WIRE)--Jul 6, 2007 - BusinessWeek todaypublished an article discussing the race by pharmaceutical andbiotechnology companies to be first to bring to market an effectiveangiogenesis treatment for cardiovascular disease. Whileangiogenesis therapies are being pursued by Sanofi-Aventis, BostonScientific, Baxter, and Genzyme, among others, the articlehighlights a very...

Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease

- Publication of New Cardiovascular Target from Lexicon's GeneticResearch - THE WOODLANDS, Texas, July 02, 2007 /PRNewswire-FirstCall/ --Lexicon Pharmaceuticals, Inc. today reported results frompreclinical research demonstrating that antibodies directed to apotential new target, angiopoietin-like protein 4 (ANGPTL4),rapidly lower triglycerides and cholesterol. Research suggests thata mon...

Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease

Adult stem cells cultivated from patients' own blood canpotentially improve the quality of life for patients whose lowerextremities are affected by peripheral vascular disease, accordingto a study in China. SHENZHEN, China, July 02, 2007 /PRNewswire/ -- BeikeBiotechnology Co., Ltd. (<a target="_blank" href="http://www.beikebiotech.com/">http://www.beikebiotech.com )today announced tha...

ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model

KOS, Greece--(BUSINESS WIRE)--Jun 26, 2007 - Acceleron Pharma,Inc., a biopharmaceutical company developing therapeutics for thetreatment of musculoskeletal, metabolic and cancer-relateddiseases, today announced results demonstrating that ACE-011, anovel anabolic bone agent for the treatment of bone loss, preservedbone mass and architecture in a murine model of multiple myeloma.Multiple myel...

Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimer's Disease

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 26, 2007 - SirtrisPharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical companyfocused on discovering and developing small molecule drugs to treatdiseases of aging, announced today that activation of SIRT1, amember of the sirtuin family of enzymes, was shown to protectagainst neurodegenerative diseases such as Alzheimer's Disease andAmyotrophic Lat...

Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinson's Disease

FORT LEE, N.J.--(BUSINESS WIRE)--Jun 21, 2007 - Neurologix, Inc.(OTCBB:NRGX) today announced the publication in the June 23 issueof the journal The Lancet of positive results from the first evergene therapy trial for Parkinson's disease and the first report ofdirect gene transfer into a patient's own brain cells for any adultneurodegenerative disease. The open label Phase 1 study, conduct...

Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine

SAN FRANCISCO & NEW DELHI, India--(BUSINESS WIRE)--Jun 21, 2007- The Institute for OneWorld Health, a US-based non-profitpharmaceutical company, today announced that Phase 3 researchrelated to its first approved drug product, Paromomycin IMInjection (Paromomycin), was published in the current issue of TheNew England Journal of Medicine (NEJM). This clinical trial showsthat the medicine...

Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -

DOYLESTOWN, Pa., June 20, 2007 /PRNewswire-FirstCall/ -- QuigleyPharma, <a target="_blank" href="http://www.quigleypharma.com/">www.QuigleyPharma.com , a whollyowned subsidiary of The Quigley Corporation announced today that ithas completed a follow-up study to evaluate the impact of QR-443 onlevels of a pro-inflammatory cytokine Interleukin-6 (IL-6) in acachexia model. This new data...

Pluristem's PLX Cells Demonstrate Potential to Treat Parkinson's Disease

NEW YORK--(BUSINESS WIRE)--Jun 14, 2007 - Pluristem Life Systems,Inc. (OTCBB:PLRS) (DAX:PJT), a bio-therapeutics Company dedicatedto the commercialization of products for a variety of malignant,degenerative and auto-immune indications, announced today thatPluristem's PLacenta eXpanded (PLX) cells have been demonstrated invitro to have properties that the Company believes gives thesecells th...

Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus

-LymphoStat-B(R) significantly reduced signs and symptoms of SLEdisease at 52 Weeks and demonstrated durable clinical andbiological activity at 76 weeks- ROCKVILLE, Md., June 14, 2007 /PRNewswire-FirstCall/ -- HumanGenome Sciences, Inc. today announced the presentation of Phase 2trial data demonstrating that LymphoStat-B(R) (belimumab)significantly reduced disease activity across multiple...

Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimer's Disease at International Conference on Prevention of Dementia

BROOMFIELD, Colo., June 11, 2007 /PRNewswire/ -- Accera, Inc.today is presenting data from an open-label extension of its PhaseIIb clinical trial of AC-1202 (Ketasyn) in Alzheimer's disease (AD)at the Alzheimer's Association's International Conference onPrevention of Dementia in Washington, D.C. Consistent with thefindings of earlier clinical and preclinical studies, AC-1202 wasshown to...

Ivivi's PEMF Technology Significantly Improves Neuron Survival in Parkinson's Disease Model, Study Finds

NORTHVALE, N.J.--(BUSINESS WIRE)--Jun 12, 2007 - Proprietary PulsedElectromagnetic Field (PEMF) technology, developed by IviviTechnologies, Inc. (AMEX:II), improved neuron survival in astandard animal cell model of brain inflammation, researchersreported today in a platform presentation at theBioelectromagnetics Society (BEMS,http://www.bioelectromagnetics.org) Annual Meeting, in Kanazawa,...

Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimer's ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification

SALT LAKE CITY, UT, June 11, 2007 (MARKET WIRE via COMTEX NewsNetwork) -- Myriad Genetics, Inc. (NASDAQ: MYGN) (<a target="_blank" href="http://www.myriad.com/">www.myriad.com )announced today that it presented a mathematical comparison of a"Staggered Start" and a "Randomized Withdrawal" clinical trialdesign with a "Natural History Staggered Start" clinical trialdesign at the Alzheime...

Treating Heart Disease Risk Factors May Slow Alzheimer's Disease Progression

- Late Life Weight Loss and "Motivational Reserve" May Also AffectAlzheimer's Risk - WASHINGTON, June 10, 2007 /PRNewswire-USNewswire/ -- A new studysuggests that treating risk factors for heart disease and stroke,such as high blood pressure and diabetes, may slow the progressionof Alzheimer's disease, according to research reported today at the2nd Alzheimer's Association International Co...

Medivation's Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimer's Disease Trial After One Year of Therapy

- Aggregate Benefit over Placebo Larger at One Year than at SixMonths - SAN FRANCISCO and WASHINGTON, June 11, 2007/PRNewswire-FirstCall/ -- Medivation, Inc. today announced that thebenefits of Dimebon over placebo in its double-blind,placebo-controlled Phase 2 study in mild-to- moderate Alzheimer'sdisease were statistically significant on all five study endpointsat 12 months. Importantl...

Clinical Update - Debio 9902 (ZT-1) for Alzheimer's Disease

Presentation of Final Phase I Monthly Implant and Phase IIa DailyOral Results LAUSANNE, Switzerland, June 11, 2007 /PRNewswire/ -- DebiopharmGroup (Debiopharm), a global independent biopharmaceuticaldevelopment specialist in oncology and serious medical conditions,presented final results of two Debio 9902 (formerly ZT-1) studiesfor the treatment of Alzheimer's disease (AD) at the Alzheime...

IMPAX Presents at Movement Disorder Society's 11th International Congress of Parkinson's Disease and Movement Disorders

HAYWARD, Calif.--(BUSINESS WIRE)--Jun 8, 2007 - IMPAX Laboratories,Inc. (OTC:IPXL) today announced that two poster presentations,highlighting the company's compound, IPX054, a combined immediate-and extended-release carbidopa/levodopa (CD/LD) product to bemarketed as VADOVA(TM), were presented at the Movement DisorderSociety's 11th International Congress of Parkinson's Disease andMovement D...

Promising Data on Cognitive Effects of Safinamide in Early Parkinson's Disease

• Data presented at Movement Disorder Society’s 11thInternational Congress • Management of cognitive impairment in earlyParkinson’s disease patients is a critical unmet medicalneed Geneva, Switzerland, June 8, 2007 – Merck Serono S.A.(virt-x: SEO) and its partner Newron Pharmaceuticals S.p.a. (SWX:NWRN) announced today data, which suggest tha...

International Movement Disorder Specialists Receive New Information About the Use of Once-Daily Azilect in the Treatment of Parkinson's Disease

Results presented at the Movement Disorder Society's 11thInternational Congress in Istanbul, Turkey KANSAS CITY, Mo., June 08, 2007 /PRNewswire-FirstCall/ -- Newinformation on the use of AZILECT(R) (rasagiline tablets) for thetreatment of Parkinson's disease (PD) was reported this week at TheMovement Disorder Society's congress in Istanbul, Turkey.Once-daily AZILECT was approved by the FD...

Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimer's Disease Study

SAN FRANCISCO, June 05, 2007 /PRNewswire-FirstCall/ --Medivation, Inc. today announced that it will hold a teleconferenceat 8:30 a.m. Eastern time on Monday, June 11, to discuss top-line12-month results from its randomized, double-blind,placebo-controlled Phase 2 clinical trial of Dimebon(TM), its leadproduct candidate, in Alzheimer's disease. Rachelle Doody, M.D., Ph.D., lead inve...

Faust Pharmaceuticals' Phase IIa Results for Parkinson's Disease Presented at International Congress of Parkinson's Disease and Movement Disorders

Faust's lead molecule, FP0011, exhibited a differentiatedcombination of therapeutic effects and good tolerance in mid- tolate-stage patients STRASBOURG, France, June 6, 2007 - Faust Pharmaceuticals S.A., aclinical stage product company specializing in the discovery anddevelopment of drugs for diseases of the nervous system, todayannounced that the Phase IIa clinical trial results of its s...

New Data Confirms Significant Improvement of Disease Signs and Symptoms in Patients with Rheumatoid Arthritis

Second Multinational Phase III Study Provides Further Evidence ofthe Significant Role of IL-6 Receptor Inhibition in the Treatmentof Rheumatoid Arthritis BASEL, Switzerland, June 6, 2007-Roche announced today thatToward (1), the second multinational phase III Actemra(tocilizumab) study, successfully reached its primary endpoint andshowed that a greater proportion of patients treated with...

Cogane Data Presented at ‘11th International Congress of Parkinson’s Disease and Disorders’

GODMANCHESTER, England - (5 June 2007) -Phytopharm plc (LSE: PYM) ("Phytopharm" or the "Company") announcestoday pre-clinical data showing that Cogane(tm) reverses thechanges in the area of the brain involved in Parkinson's disease.This data will be presented by Dr Jonathan Brotchie, aninternationally recognised expert on Parkinson's disease at 'The11th International Congres...

Caelyx Delays Time to Disease Progression as Maintenance Therapy in Patients with Metastatic Breast Cancer

CHICAGO - June 3, 2007 - Schering-Plough Corp. announced resultsfrom a Phase III study that showed maintenance chemotherapy withCaelyx (pegylated liposomal doxorubicin hydrochloride)significantly prolonged time to progression (TTP) in patients withmetastatic breast cancer with infrequent and manageable clinicaltoxicity after first-line chemotherapy. These data were presentedtoday at the...

8-Year Long-term Data Demonstrate Prolonged Overall Survival and Length of Disease Remission with Bexxar

Positive Results in Patients With Follicular Lymphoma ReportedToday at ASCO Annual Meeting PHILADELPHIA, June 04, 2007 /PRNewswire/ -- GlaxoSmithKline plcannounced today long-term efficacy data from a Phase II trial of asingle one-week course of frontline treatment with the BEXXAR(R)Therapeutic Regimen (Tositumomab and Iodine I-131 Tositumomab) in76 patients with newly diagnosed advanced...

Hyperthermia Plus Chemotherapy Nearly Doubles Disease-Free Survival Compared to Chemotherapy Alone for Sarcoma Cancer Patients

SALT LAKE CITY, June 04, 2007 /PRNewswire-FirstCall/ -- BSDMedical Corp. announced today that the results of a 340 patientrandomized Phase III clinical trial testing the benefit of addinghyperthermia therapy to chemotherapy were presented at the annualAmerican Society of Clinical Oncology (ASCO) conference underway inChicago, Illinois. According to the results of this clinical study,whic...

MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations

Data Include Results from Phase 1 Studies with Monoclonal AntibodyTargeting Interleukin-9 (IL-9); Preclinical Data Provide FurtherRationale for IL-9 Inhibition in Developing Potential AsthmaTherapies GAITHERSBURG, Md., May 24, 2007 /PRNewswire-FirstCall/ --MedImmune, Inc. today announced the presentation of datahighlighting recent progress within the company's inflammatorydisease pipelin...

ChemoCentryx Presents Positive Phase 2 Clinical Data for Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007 Conference

Clear Anti-Inflammatory Activity Demonstrated Among Patients withActive Disease MOUNTAIN VIEW, Calif., May 23, 2007 /PRNewswire/ --ChemoCentryx, Inc., a clinical-stage biopharmaceutical companyfocused on discovering, developing and commercializingorally-administered therapeutics that target the chemokine system,presented data today from the company's Phase 2 clinical trial ofTraficet-EN...

Aquavan (Fospropofol Disodium) Injection Data Presented at Digestive Disease Week 2007

MINNEAPOLIS, May 23, 2007 (BUSINESS WIRE) -- MGI PHARMA, INC.(NASDAQ:MOGN), a biopharmaceutical company focused in oncology andacute care, today announced the presentation of results of asuccessful pivotal phase 3 trial of Aquavan(R) (fospropofoldisodium) Injection in patients undergoing colonoscopy. Primary andsecondary efficacy endpoint results, as well as safety data, werepresented at...

Phase 2a Diarrhea Predominant Irritable Bowel Syndrome Results from 2006 Presented at Digestive Disease Week in Washington, D.C.

SOUTH SAN FRANCISCO, Calif., May 23, 2007 /PRNewswire-FirstCall/-- Napo Pharmaceuticals, Inc., , which focuses on the developmentand commercialization of proprietary pharmaceuticals for the globalmarketplace in collaboration with local partners, announced thatTrine Pharmaceuticals, Inc. ("Trine") is presenting a posterdetailing the results of a Phase 2a study conducted in 2006 forcrofele...

Enzo Biochem Individualized Oral Immune Regulation Therapy May Be Effective Approach to Treating Crohn's Disease

WASHINGTON--(BUSINESS WIRE)--May 22, 2007 - Alequel(TM), anindividualized oral immune regulation preparation, may be aneffective treatment for moderate-to-severe Crohn's disease. Interimdata from two ongoing double-blind, placebo controlled Phase IIstudies suggest that this investigational approach induced goodclinical remissions and improved patients' quality of life comparedto placebo. Me...

Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease

BARCELONA, Spain, May 22, 2007 /PRNewswire/ -- A three-yearfollow-up subset analysis presented today as a late-breakingclinical trial at EuroPCR 2007 showed that the CYPHER(R)Sirolimus-eluting Coronary Stent had results comparable to coronaryartery bypass grafting (CABG or bypass surgery) and better outcomesthan bare metal stents (BMS) in diabetic patients with blockages intw...